Open AccessJournal Article
The emergence of triglycerides as a significant independent risk factor in coronary artery disease
TLDR
The Prospective Cardiovascular Münster (PROCAM) study showed that fasting levels of triglycerides were an independent risk factor for CHD events, irrespective of serum levels of high density lipoprotein cholesterol (HDL-C) or low density cholesterol (LDL-L), and that individuals with potentially atherogenic lipid profiles should be managed initially through the introduction of lifestyle changes.Abstract:
The Prospective Cardiovascular Munster (PROCAM) study involved 4849 middle-aged men who were followed up for 8 years to record the incidence of coronary heart disease (CHD) events according to the risk factors present at study entry. The study showed that fasting levels of triglycerides were an independent risk factor for CHD events, irrespective of serum levels of high density lipoprotein cholesterol (HDL-C) or low density lipoprotein cholesterol (LDL-C). Other independent predictors of CHD included serum levels of LDL-C and HDL-C, age, systolic blood pressure, cigarette smoking, diabetes mellitus, a family history of myocardial infarction and angina pectoris, but did not include total serum cholesterol levels. Individuals with an LDL-C/HDL-C ratio > 5 had a 19.2% chance of experiencing a CHD event in the next 8 years. Furthermore, if an LDL-C/HDL-C ratio > 5 was combined with hypertriglyceridaemia (> or = 2.3 mmol. l-1), the risk of CHD increased to 26.9%. The association between hypertriglyceridaemia and CHD events may be related to the presence of atherogenic, triglyceride-rich particles in plasma, such as LDL and very low density lipoproteins. High triglyceride levels may also predispose to thrombosis. Individuals with potentially atherogenic lipid profiles should be managed initially through the introduction of lifestyle changes. However, if these fail to achieve recommended target values, lipid-lowering therapy should be considered.read more
Citations
More filters
Journal ArticleDOI
ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina)
Raymond J. Gibbons,Jonathan Abrams,Kanu Chatterjee,Jennifer Daley,Prakash Deedwania,John S. Douglas,T. Bruce Ferguson,Stephan D. Fihn,Theodore D. Fraker,Julius M. Gardin,Robert A. O'Rourke,Richard C. Pasternak,Sankey V. Williams,Joseph S. Alpert,Elliott M. Antman,Loren F. Hiratzka,Valentin Fuster,David P. Faxon,Gabriel Gregoratos,Alice K. Jacobs,Sidney C. Smith +20 more
TL;DR: The Clinical Efficacy Assessment Subcommittee of the American College of Physicians–American Society of Internal Medicine acknowledges the scientific validity of this product as a background paper and as a review that captures the levels of evidence in the management of patients with chronic stable angina as of November 17, 2002.
Journal ArticleDOI
Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology
TL;DR: The approaches described in this statement can be used for guidance at several levels of primary prevention; however, the statement does not attempt to specifically link risk assessment to treatment guidelines for particular risk factors, but provides critical background information that could be used in the development of new treatment guidelines.
Journal ArticleDOI
American association of clinical endocrinologists and american college of endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease
Paul S. Jellinger,Yehuda Handelsman,Paul D. Rosenblit,Zachary T. Bloomgarden,Vivian Fonseca,Alan J. Garber,George Grunberger,Chris K. Guerin,David S.H. Bell,Jeffrey I. Mechanick,Rachel Pessah-Pollack,Kathleen Wyne,Donald A. Smith,Eliot A. Brinton,Sergio Fazio,Michael H. Davidson,Farhad Zangeneh,Michael A. Bush +17 more
TL;DR: This CPG is a practical tool that endocrinologists, other health care professionals, health-related organizations, and regulatory bodies can use to reduce the risks and consequences of dyslipidemia.
Journal ArticleDOI
Metabolic syndrome: Connecting and reconciling cardiovascular and diabetes worlds
TL;DR: Primary treatment of the metabolic syndrome is lifestyle therapy--weight loss, increased physical activity, and anti-atherogenic diet, but as the condition progresses, drug therapies directed toward the individual risk factors might be required.
Journal ArticleDOI
National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report
Terry A. Jacobson,Matthew K. Ito,Kevin C. Maki,Carl E. Orringer,Harold E. Bays,Peter B. Jones,James M. McKenney,Scott M. Grundy,Edward A. Gill,Robert A. Wild,Don P. Wilson,W. Virgil Brown +11 more
TL;DR: This document provides support for a consensus set of recommendations for patient-centered management of dyslipidemia in clinical medicine and an elevated level of cholesterol carried by circulating apolipoprotein B-containing lipoproteins is a root cause of atherosclerosis.
Related Papers (5)
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
Scott M. Grundy,David W. Bilheimer,Alan Chait,Luther T. Clark,Margo A. Denke,Richard J. Havel,William R. Hazzard,Stephen B. Hulley,Donald B. Hunninghake,Robert A. Kreisberg,Penny M. Kris-Etherton,James M. McKenney,Michael A. Newman,Ernst J. Schaefer,Burton E. Sobel,Carolyn Somelofski,Milton C. Weinstein,H. Bryan Brewer,James I. Cleeman,Karen A. Donato,Nancy D. Ernst,Jeffrey M. Hoeg,Basil M. Rifkind,Jacques E. Rossouw,Christopher T. Sempos,Joanne M. Gallivan,Maureen N. Harris,Laurie Quint-Adler +27 more